Until recently, unless considered for clinical trial involving targeted therapies, or limited by patient’s age or co-morbid conditions, one does not need to know the cytogenetic (except in cases with core binding factor AML where early addition of Gemtuzumab with induction may have additional value) or molecular profile to start induction therapy in non-APL AML, even in FLT3-ITD-positive cases where midostaurin is started on day 85. This evidence concerns the gene FLT3 and acute myeloid leukemia.